RaySearch Laboratories AB (publ) today announced the release of RayIntelligence® v2026, the latest version of its oncology analytics system. The new version deepens integration across RaySearch’s product portfolio, connecting with RayStation® and RayCare® – and marks a significant step forward in helping cancer centers turn fragmented data into actionable insights for continuous improvement.
Radiation oncology generates ever increasing amounts of clinical data, but fragmentation across systems makes evidence-based improvement challenging. RayIntelligence connects directly to primary data sources, giving clinical teams the intelligence they need to run a continuously improving oncology program, with standardized care, optimized resource utilization, workflow efficiency, and operations that learn from every patient treated.
What's New in RayIntelligence v2026
AI performance monitoring
RayIntelligence v2026 introduces a new monitoring functionality, beginning with deep learning segmentation (DLS) performance monitoring. This capability enables institutions to systematically track and evaluate the performance of RayStation DLS in clinical use, providing the transparency and accountability that safe AI adoption in healthcare demands.
Improved plan benchmarking across patient cohorts
The upgraded plan set comparison module introduces powerful benchmarking capabilities that allow clinical teams to compare plan quality across defined patient cohorts. Teams can now track trends over time, identify habitual deviations, and perform detailed dosimetric comparisons, creating a robust foundation for evidence-based protocol refinement and peer review.
Clinic-specific data modeling and customization
Recognizing that no two oncology programs are identical, RayIntelligence v2026 offers a high level of customization that enables clinic-specific data modeling. Institutions can configure the platform to reflect their own workflows, patient populations, and clinical priorities, ensuring that the intelligence generated is meaningful, actionable, and directly relevant to their context.
Strengthening clinical team expertise
Building on this customization capability, RayIntelligence v2026 gives institutions visibility into planning experience across their clinical team. By mapping each planner's experience across different cancer types and how their clinical practice evolves over time, institutions gain the insights needed to drive strategic professional development and strengthen the team where it matters most.
“With RayIntelligence v2026, we continue to advance data-driven oncology through new capabilities,” says Johan Löf, founder and CEO of RaySearch Laboratories. “These tools help clinics leverage analytics to monitor performance, benchmark treatment plans, and drive continuous, evidence-based improvement in cancer care.”
For more information, please contact:
Johan Löf, founder and CEO, RaySearch Laboratories AB
Tel: +46 (0) 8 510 530 00
Carolina Strömlid, Head of Investor Relations, RaySearch Laboratories AB
Tel: +46 (0) 708 807 173
ir@raysearchlabs.com
About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure, and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems. RaySearch’s software has been sold to over 1,200 clinics in 51 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003 (STO: RAY B). More information is available at raysearchlabs.com.
* Subject to regulatory clearance in some markets.